SOTAHEXAL

This brand name is authorized in Austria, Brazil, Estonia, Germany, Poland, Singapore, South Africa.

Active ingredients

The drug SOTAHEXAL contains one active pharmaceutical ingredient (API):

1	Sotalol UNII HEC37C70XX - SOTALOL HYDROCHLORIDE
	D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties.
	Read more about Sotalol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AA07	Sotalol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective
Discover more medicines within C07AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	511510301115416, 511513100057903, 511514090059103
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	07254206, 07254212, 07254229, 07561026, 07561049, 07704968, 07704980
EE	Ravimiamet	1034480, 1071863, 1678169, 1678170
PL	Rejestru Produktów Leczniczych	100062357, 100062363, 100118371
SG	Health Sciences Authority	13311P
ZA	Health Products Regulatory Authority	29/5.2/0749, 29/5.2/0750